Neurelis was founded to license, develop, and commercialize product candidates for epilepsy, psychiatry, and the broader central nervous system (CNS) market with an emphasis on rescue therapies that empower patients, caregivers, and healthcare providers. Our extensive expertise in the development and commercialization of CNS compounds, combined with our strong relationships with leading researchers and clinicians in these markets, allows us to advance the development of unique product candidates that address significant unmet medical needs.
Clear unmet need for additional seizure rescue options with different routes of delivery.
Multiple challenges encountered with nasal administration.
Diazepam formulated with technology platform to create NRL-1.
Pre-clinical trial initiated for NRL-1.
Pre-IND meeting with FDA
Manufacturing facility transfer in preparation for clinical & commercial supply.
Orphan Drug designation granted by FDA.
phase 3 clinical program for NRL-1.
Series B financing secured.
NRL-1 granted Fast Track designation by FDA.
Preparation for NDA filing